🇺🇸 FDA
Patent

US 12303724

Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12303724 (Non-adult human dosing of anti-CD30 antibody-drug conjugates for treatment of hematological or lymphoid cancer) held by Takeda Pharmaceutical Company Limited expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue May 20 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K2039/55, A61K31/475